Yubo International Biotech Ltd

Yubo International Biotech Ltd. filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The company reported a net loss of $203,726 for the third quarter of 2026, an improvement from the $310,152 net loss in the same quarter of 2025. However, for the nine-month period, the net loss widened to $767,473 from $902,288 in the prior year. The company's total assets decreased, while total liabilities and shareholders' deficit increased, indicating a challenging financial position.

Yubo International Biotech Ltd. reported a net loss of $(295,026) for the first quarter ended March 31, 2026, an improvement from a net loss of $(467,318) in the prior-year period. The company continued to report zero revenue from sales of products and services. Operating expenses decreased to $289,274, down from $467,299 year-over-year. The company's total assets declined to $709,872, while total liabilities increased to $3,019,451, resulting in a growing shareholders' deficit of $(2,309,579).